perjeta concentrate for solution for infusion 420mg14ml
roche singapore pte. ltd. - pertuzumab - infusion, solution concentrate - 30 mg/ml - pertuzumab 30 mg/ml
perjeta 420mg14ml concentrate for solution for infusion vials
roche products ltd - pertuzumab - solution for infusion - 30mg/1ml
perjeta concentrate for solution for infusion
roche diagnostics gmbh - pertuzumab - concentrate for solution for infusion - 30mg/ml
perjeta concentrate for solution for infusion
f. hoffmann-la roche ltd. - pertuzumab - concentrate for solution for infusion - 30mg/ml
perjeta
roche registration gmbh - pertuzumab - breast neoplasms - antineoplastic agents, monoclonal antibodies - metastatic breast cancer:perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.neoadjuvant treatment of breast cancer:perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
perjeta 420 mg concentrate for solution for infusion
roche, switzerland - pertuzumab - concentrate for solution for infusion - 420 mg
perjeta 420mg vial 420 mg/14ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - pertuzumab 420 mg/14ml - 420 mg/14ml
perjeta 420mg concentrate for solution for infusion
f. hoffman-la roche ltd, basel grenzacherstrasse 124 ch-4070 basel, switzerland - pertuzumab - concentrate for solution for infusion - one 14 ml vial of concentrate contains 420 mg of - pertuzumab
perjeta
roche products (nz) ltd - pertuzumab 420mg equivalent to 30 mg/ml - concentrate for infusion - 420 mg/14ml - active: pertuzumab 420mg equivalent to 30 mg/ml excipient: glacial acetic acid histidine polysorbate 20 sucrose water for injection - metastatic breast cancer perjeta is indicated in combination with trastuzumab and docetaxel for patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for their metastatic disease.
perjeta
roche diagnostics gmbh - pertuzumab - concentrate for solution for infusion - 30mg/ml